Personal Care Products

GIANT BIOGENE

China Securities Maintains Buy Rating for Juzi Bio with Target Price

Juzi Bio Sees First Revenue and Net Profit Decline

Juzi Biotech Reports Revenue and Profit Decrease in 2025

Juzi Biological Announces Full-Year 2025 Financial Report

Goldman Sachs Maintains Buy Rating on Giant Biogene with Price Target at HKD 46

Citi Downgrades Earnings Forecast for Jubilife Biotech but Maintains Buy Rating

GIANT BIOGENE released FY2025 9 Months Earnings on March 19 (BJT), actual revenue HKD 4.685 B, actual EPS HKD 1.5971

GIANT BIOGENE released FY2025 Q3 earnings on March 19 (BJT), actual revenue HKD 1.315 B, actual EPS HKD 0.374

Juzi Bio Announces 2025 Earnings with Revenue Decline

GIANT BIOGENE released FY2025 Q4 earnings on March 19 After-Market (BJT), actual revenue HKD 1.338 B, actual EPS HKD 0.3804

GIANT BIOGENE released FY2025 earnings on March 19 After-Market (BJT), actual revenue HKD 6.032 B (forecast HKD 6.582 B), actual EPS HKD 1.9782 (forecast HKD 2.2435)

GIANT BIOGENE to Release FY2025 Earnings on March 19 After-Market (BJT), Forecast Revenue HKD 6.699 B, EPS HKD 2.2433

Chief Scientist of Juzi Bio Purchased Shares Worth HKD 2.5 Billion

Juzi Bio repurchased 400,000 shares for approximately HKD 14.3467 million

Shaanxi Juzi Biotech Co., Ltd. Obtains Medical Device Registration Certificate for Reconstituted Collagen and Sodium Hyaluronate Composite Solution

Juzi Bio repurchased 400,000 shares

Juzi Biosciences Repurchased 400,000 Shares at HKD 34.12-34.44 per Share

Juzi Biotech Repurchased 400,000 Shares for HKD 13,581,600

Juzi Biotech Grants Nordberg Medical Global Rights to Recombinant Collagen Development

FAMEGLOW

NEW GONOW RV

TJCD

REALWAY CAPITAL

ZHONGSHENJIANYE

51WORLD

CENTRAL DEV H

ZXZN QI-HOUSE

MEGAIN

GREEN BROAD

Special dividend (cash)

Ex Date: 2026.06.01, Special dividend 0.7629 HKD

Ordinary dividend (cash)

Ex Date: 2026.06.01, Cash dividend 0.6124 HKD

02367

Giant Biogene Holding Co. Ltd. has scheduled its annual general meeting for May 28, 2026, in Xi’an. Shareholders will review the 2025 financial statements and vote on the re-election of three executive directors and the appointment of KPMG as the new auditor. The meeting will also address mandates for share repurchase and issuance, potentially impacting capital management and shareholder returns. The current analyst rating for the stock (HK:2367) is a Buy with a price target of HK$38.70.

Tip Ranks

Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor

Giant Biogene Holding Co. Ltd. (HK:2367) is set to replace Ernst & Young with KPMG as its auditor after a seven-year tenure. This decision follows a corporate governance review and will be presented for shareholder approval at the upcoming annual general meeting. EY will complete the audit for the year ending December 31, 2025, with no expected disruptions to the audit schedule. The audit committee cited KPMG's technical competence and resources as key factors in their decision. The current analyst rating for the stock is a Hold with a price target of HK$35.00.

Giant Biogene Moves to Replace EY With KPMG as Auditor

Citic Securities analyst maintained a Buy rating on Giant Biogene Holding Co. Ltd. on April 22 and set a price target of HK$40.00. The company’s shares closed yesterday at HK$32.02.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Giant Biogene Holding Co. Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$40.06.

CITIC SEC

CITIC Securities Co., Ltd.

Citic Securities Sticks to Its Buy Rating for Giant Biogene Holding Co. Ltd. (2367)

159837

516500

159849

516930

GF Securities analyst maintained a Buy rating on Giant Biogene Holding Co. Ltd. yesterday and set a price target of HK$33.66.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Strong Buy analyst consensus rating for Giant Biogene Holding Co. Ltd. with a HK$43.45 average price target.

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

Giant Biogene Holding Co. Ltd. (2367) Receives a Buy from GF Securities

In a report released yesterday, from Goldman Sachs maintained a Buy rating on Giant Biogene Holding Co. Ltd., with a price target of HK$46.00.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Giant Biogene Holding Co. Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$48.53.

Goldman Sachs Reaffirms Their Buy Rating on Giant Biogene Holding Co. Ltd. (2367)

688363

In mid-2025, a "industry-level public opinion controversy" with Bloomage Biotech pushed GIANT BIOGENE to the forefront. This dispute is not only about the restructuring of collagen

- In mid-2025, a public controversy involving Gigi Biological and Huaxi Biological escalated tensions, impacting Gigi's flagship collagen brand, Kefu Mei, over claims of misrepresented collagen content.  
- Despite a slight revenue decline to 55.18 billion yuan and a net profit drop of 7.15%, Kefu Mei saw a 1.6% decrease in sales, while another brand, Keli King, experienced a 9.2% growth, attributed to online expansion.  
- Looking ahead to 2026, Gigi Biological aims to regain growth through enhanced medical aesthetics business and new product developments, following a year of challenges that revealed shortcomings in product standards.

Wallstreetcn

Bloomage Biotech

After the "glass glue war," GIANT BIOGENE shows its first signs of growth anxiety

Giant Biogene Holding Co. Ltd. has announced a special cash dividend of RMB 0.6714 per share for the financial year ending December 31, 2025, reflecting management's confidence in its cash position. The dividend, pending shareholder approval on May 28, 2026, will be paid in Hong Kong dollars on June 25, 2026. This decision aims to reward shareholders while maintaining financial flexibility. The company's stock (HK:2367) currently holds a Buy rating with a price target of HK$36.00, appealing to income-focused investors in the biotech sector.

Giant Biogene Announces Special 2025 Dividend, Signaling Confidence in Cash Position

09992

09896

00700

The main indices of the Hong Kong stock market experienced a significant pullback during the trading session, with the Hang Seng Index, Hang Seng Tech Index, and the China Enterprises Index all declining, showing clear structural differentiation. Leading internet and technology stocks generally faced pressure, while retail and jewelry stocks exhibited mixed performance, with individual consumer chain stocks like POP MART and MNSO standing out. Short-term capital flows were active in popular varieties, as the market focused on macro data and policy changes, with investor sentiment dominated by a wait-and-see attitude

- The Hong Kong stock market shows a general decline, with the Hang Seng Index dropping 1.24% and unable to surpass previous highs.  
- The technology sector struggles, particularly Tencent and Kuaishou, while the retail sector sees mixed results; Alibaba falls 2.82%, but Miniso rises 4.58%.  
- Macro factors such as economic data fluctuations and liquidity concerns influence investor sentiment and market dynamics.

Market Pulse

POP MART

MNSO

TENCENT

KUAISHOU-W

BIDU-SW

BABA-W

JD-SW

CTG DUTY-FREE

CHOW TAI FOOK

BRAINAURORA-B

MODERN LAND

GUOFUHEE

MACAU E&M

FI CSOP HSI

FL2 CSOP HSI

CSOP HS TECH

FI2 CSOP HSI

Hong Kong stocks intraday | All three major indices retraced, Tencent Holdings weakened while POP MART remained active against the trend

GIANT BIOGENE(02367.HK)